⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ENTX News
Entera Bio Ltd. Ordinary Shares
Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE
prnewswire.com
ENTX
Form 8-K
sec.gov
ENTXW
ENTX
Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement
globenewswire.com
ENTX
Form 8-K
sec.gov
ENTX
Parent Project Muscular Dystrophy Hosts 2026 Annual Conference in Orlando, Florida
prnewswire.com
CAPR
SRPT
CATX
BMRA
EDSA
ENTX
SLDB
WVE
Positive FDA Feedback on Phase 3 Brings Entera Bio's Oral Osteoporosis Pill One Step Closer to Market
globenewswire.com
ENTX
Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis
globenewswire.com
ENTX
Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026
globenewswire.com
ENTX
OPK
ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)
globenewswire.com
ENTX
Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation
globenewswire.com
ENTX